CUDC-101

CAT: 0804-HY-10223-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-10223-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
CAS Number
[1012054-59-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
EGFR; HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CUDC-101.html
Purity
99.05
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
C#CC1=CC=CC(NC2=NC=NC3=CC(OC)=C(C=C23)OCCCCCCC(NO)=O)=C1
Molecular Formula
C24H26N4O4
Molecular Weight
434.49
Precautions
H302, H315, H319, H335
References & Citations
[1]Xiong Cai et al Discovery of 7- (4- (3-Ethynylphenylamino) -7-methoxyquinazolin-6-yloxy) -N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer J. Med. Chem., 2010, 53 (5), pp 2000–2009|[2]Sun H, et al. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Horm Cancer. 2016 Jun;7 (3) :196-210.|[3]Zhang L, et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget. 2015 Apr 20;6 (11) :9073-85.|[4]Lai CJ, et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.Cancer Res. 2010 May 1;70 (9) :3647-56. Epub 2010 Apr 13.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
EGFR/ErbB1/HER1; ErbB2/HER2; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9

Related Products

CatalogName
HY-15835-01CUDC-427
HY-162278HSD17B13-IN-101
HY-P5642Retrocyclin-101
HY-168117HP-101
HY-117702RB 101
HY-116065CUMI-101
HY-157646-01MZ-101
HY-124805-01MAL3-101
HY-10914-01UCPH-101
HY-18964-01MG-101

Alternative Products

CatalogName
007121CUDC-101
A10246-500CUDC-101 500mg
A10246-10CUDC-101 10mg
A10246-50CUDC-101 50mg
A10246-100CUDC-101 100mg
A10246-200CUDC-101 200mg

Popular Products